Entities / Company
ReGenX Biosciences (United States).
company in Washington D.C., United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 35
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Gone quiet
No new reports in 90+ days-
Institutional shareholders now own 67% of ReGenX Biosciences as of July 18, 2025.Some support1 report
-
AbbVie and ReGenX Biosciences entered into a collaboration regarding the development of treatments for diabetic retinopathy.Some support1 report
-
Zacks ranks ReGenX Biosciences in the Medical - Biomedical and Genetics industry.Some support4 reports
-
ReGenX Biosciences developed a gene therapy for Hunter syndrome, and the FDA requested longer-term pivotal results.Some support1 report1 development inside
-
ReGenX Biosciences submitted data to the FDA in response to a request for longer-term pivotal results for its gene therapy.Some support2 reports
-
AbbVie collaborates with ReGenX Biosciences on the surabgene lomparvovec treatment platform, which is relevant to patients receiving Novartis' ZOLGENSMA®.Some support4 reports
No events began in the chosen period. Widen it, or reset.
Around ReGenX Biosciences (United States) this week
News at the entities that move ReGenX Biosciences (United States) most-
FDA StructuralFDA, LabCorp, and Charles River Laboratories formed a collaboration to evaluate the potential for medicine abuse.Moves ReGenX Biosciences (United States)
-
AbbVie OperationalAbbVie is developing ABBV-466, a potential successor to Skyrizi, whose patents may expire by 2033.Moves ReGenX Biosciences (United States)
-
Novartis StructuralSean Maenpaa, with experience at Novartis and Celgene, was appointed SVP Business Development at Clovis Oncology.Moves ReGenX Biosciences (United States)
Connections
The 4 strongest of 35, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
ReGenX Biosciences is undergoing the formal regulatory approval process, including inspections and data submission, with the FDA.
-
AbbVie Operational
AbbVie and ReGenX Biosciences maintain an ongoing operational partnership focused on joint drug development and clinical trials.
-
Novartis Structural
ReGenX Biosciences monetizes royalties from Novartis' Zolgensma, establishing a formal licensing and operational dependency.
-
Olivier Danos Structural
Olivier Danos holds executive and scientific roles at ReGenX Biosciences.
History
Events by the month they beganJune 2026
6 events- Institutional shareholders now own 67% of ReGenX Biosciences as of July 18, 2025.
- AbbVie and ReGenX Biosciences entered into a collaboration regarding the development of treatments for diabetic retinopathy.
- Zacks ranks ReGenX Biosciences in the Medical - Biomedical and Genetics industry.
- ReGenX Biosciences developed a gene therapy for Hunter syndrome, and the FDA requested longer-term pivotal results.
- ReGenX Biosciences submitted data to the FDA in response to a request for longer-term pivotal results for its gene therapy.
- AbbVie collaborates with ReGenX Biosciences on the surabgene lomparvovec treatment platform, which is relevant to patients receiving Novartis' ZOLGENSMA®.